

NxStage Medical, Inc. (NASDAQ:NXTM) has dropped 0.55% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 30.34% in the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 5.54% and the outperformance increases to 37.54% for the last 4 weeks.

For the current week, the company shares have a recommendation consensus of Buy. NxStage Medical, Inc. (NASDAQ:NXTM) rose 2.31% or 0.41 points on Friday and made its way into the gainers of the day. After trading began at \$17.47 the stock was seen hitting \$18.5 as a peak level and \$17.358 as the lowest level. The stock ended up at \$18.17. The daily volume was measured at 572,622 shares. The 52-week high of the share price is \$19.63 and the 52-week low is \$11.5. The company has a market cap of \$1,153 million. Nxstage Medical, Inc. is up 9% in the last 3-month period. Year-to-Date the stock performance stands at 1.34%. The company shares have rallied 38.28% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of \$19.63 and one year low was seen on September 16, 2014 at \$11.5. The 50-day moving average is \$15.54 and the 200 day moving average is recorded at \$16.68. S&P 500 has rallied 1.35% during the last 52-weeks. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (President) of Nxstage Medical, Inc., Turk Joseph E Jr had sold 3,252 shares worth of \$57,690 in a transaction dated August 12, 2015. In this transaction, 3,252 shares were sold at \$17.74 per share. NxStage Medical, Inc. (NASDAQ:NXTM) should head towards \$21 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to \$15 per share. The higher price estimate target is at \$24 according to the Analysts. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

...